This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Identive Technologies, AMR:Small-Cap Winners

Stocks in this article: INVE SKH EXEL AMR JBLU LCC AVII

NEW YORK ( TheStreet) -- Shares of small-caps were under pressure on Monday amid broad market weakness. Still, a handful of stocks still managed to garner investor interest.

Identive Technologies (INVE), which operates in the radio frequency identification systems (RFID) space, saw its shares more than double to $5.72.

ACiG Technology, a supplier and distributor of RFID products and a business unit of Identive Group announced that is has been selected as the exclusive supplier of near field communication RFID stickers for the roll out of Google's marketing campaign for Google Places in Austin, Texas. The NFC stickers are manufactured by ACiG's sister company, Smartag. Over 12 million shares changed hands by Monday afternoon.

Shares of nursing home operator Skilled Healthcare (SKH) were climbing 8% to $15.16 after it said late Monday that it was exploring strategic alternatives, including putting itself up for sale.

AVI Pharma (AVII) was another stock gaining in the biotech space, rising 4.3% to $1.68 after Piper Jaffray initiated coverage on the stock with an overweight rating and a $3.50 price target on the stock.

Airline stocks were gaining on Monday on the back of a retreat in crude oil prices. Shares of AMR (AMR), parent of American Airlines, was up 2.7% to $5.92. US Airways (LCC) saw its stock add 3.7% to $8.54. Shares of JetBlue Airways (JBLU) was ahead by 2%.

Exelixis (EXEL) was a standout performer in the pharmaceutical space, climbing 2.5% to $11.37. According to a Bloomberg news report, the company is said to be hiring Goldman Sachs to prepare for potential takeovers after its experimental prostate cancer drug performed well in a study.

-- Written by Shanthi Bharatwaj in New York

>To contact the writer of this article, click here: Shanthi Bharatwaj.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs